Xiao Jian, He Bixiu, Zou Yong, Chen Xi, Lu Xiaoxiao, Xie Mingxuan, Li Wei, He Shuya, You Shaojin, Chen Qiong
Department of Geriatrics, Respiratory Medicine, Xiangya Hospital of Central South University, Changsha, China.
Department of Respiratory Medicine, Xiangya Hospital of Central South University, Changsha, China.
Sci Rep. 2016 Jul 26;6:30437. doi: 10.1038/srep30437.
The prognostic value of forkhead box protein P1 (FOXP1) protein expression in tumors remains controversial. Therefore, we conducted a systematic review and meta-analysis, searching the PubMed, Embase and Web of Science databases to identify eligible studies. In total, we analyzed 22 articles that examined 9 tumor types and included 2468 patients. Overall, decreased expression of FOXP1 protein was associated with favorable overall survival (OS) in lymphoma patients (HR = 0.38, 95%CI: 0.30-0.48, p < 0.001). In patients with solid tumors, decreased FOXP1 expression correlated with unfavorable OS (HR = 1.82, 95%CI: 1.18-2.83, p = 0.007). However, when FOXP1 protein expression was nuclear, decreased expression was also associated with favorable OS (HR = 0.53, 95%CI: 0.32-0.86, p = 0.011). Furthermore, decreased FOXP1 expression resulted in the best OS in patients with mucosa-associated lymphoid tissue (MALT) lymphomas (HR = 0.26, 95%CI: 0.11-0.59, p = 0.001), but the worst OS was observed in non-small cell lung cancer (NSCLC) patients (HR = 3.11, 95%CI: 1.87-5.17, p < 0.001). In addition, decreased FOXP1 expression was significantly correlated with an unfavorable relapse-free survival (RFS) in breast cancer patients (HR = 1.93, 95%CI: 1.33-2.80, p = 0.001).
叉头框蛋白P1（FOXP1）蛋白表达在肿瘤中的预后价值仍存在争议。因此，我们进行了一项系统评价和荟萃分析，检索了PubMed、Embase和Web of Science数据库以识别符合条件的研究。我们总共分析了22篇研究文章，这些文章研究了9种肿瘤类型，纳入了2468例患者。总体而言，FOXP1蛋白表达降低与淋巴瘤患者较好的总生存期（OS）相关（HR = 0.38，95%CI：0.30 - 0.48，p < 0.001）。在实体瘤患者中，FOXP1表达降低与不良的OS相关（HR = 1.82，95%CI：1.18 - 2.83，p = 0.007）。然而，当FOXP1蛋白表达位于细胞核时，表达降低也与较好的OS相关（HR = 0.53，95%CI：0.32 - 0.86，p = 0.011）。此外，FOXP1表达降低在黏膜相关淋巴组织（MALT）淋巴瘤患者中导致最佳的OS（HR = 0.26，95%CI：0.11 - 0.59，p = 0.001），但在非小细胞肺癌（NSCLC）患者中观察到最差的OS（HR = 3.11，95%CI：1.87 - 5.17，p < 0.001）。此外，FOXP1表达降低与乳腺癌患者不良的无复发生存期（RFS）显著相关（HR = 1.93，95%CI：1.33 - 2.80，p = 0.001）。
